Michael Cardone leads Eutropics’ scientific efforts to achieve corporate milestones. The company develops novel predictive diagnostic tools for personalized medicine. The new platform measures cellular mechanisms that regulate apoptosis. This platform is providing compositions and methods for assessing therapeutic approaches for blood and solid cancers and providing personalized treatments for individual patients. His experience includes 20 years of scientific and business management at early to mid-stage biotech companies. Prior to Eutropics, he was a scientific co-founder of publicly traded Merrimack Pharmaceuticals, a Cambridge, MA-based company where he worked with the starting team to develop the oncology program. Prior to this, he worked at MIT developing tools for small molecule drug target identification and validation. He received a Ph.D. in cell biology at UCSF and completed post-doctoral studies in apoptosis signaling at the Burnham Institute in La Jolla, CA.
Prediction of Tumor Cell Response to Therapy
Eutropics' unique panel of antibodies, “PRIMABs”, enable detection of tumor cell mitochondrial priming, a key determinant of cancer responsiveness to treatments. The presence (or absence) of the critical pro-survival : pro-apoptotic protein complexes, is used as a predictive biomarker for personalized medicine. Such reagents have hitherto not been available.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.